HK1179957A1 - Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes hsl - - Google Patents
Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes hsl -Info
- Publication number
- HK1179957A1 HK1179957A1 HK13107152.4A HK13107152A HK1179957A1 HK 1179957 A1 HK1179957 A1 HK 1179957A1 HK 13107152 A HK13107152 A HK 13107152A HK 1179957 A1 HK1179957 A1 HK 1179957A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hsl
- spiro
- diabetes
- treatment
- inhibitors useful
- Prior art date
Links
- 125000000113 cyclohexyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09173178 | 2009-10-15 | ||
| PCT/EP2010/065232 WO2011045292A1 (en) | 2009-10-15 | 2010-10-12 | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1179957A1 true HK1179957A1 (en) | 2013-10-11 |
Family
ID=43093680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13107152.4A HK1179957A1 (en) | 2009-10-15 | 2013-06-19 | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes hsl - |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8440710B2 (xx) |
| EP (1) | EP2488493B1 (xx) |
| JP (1) | JP5749272B2 (xx) |
| KR (1) | KR101576328B1 (xx) |
| CN (1) | CN102858743B (xx) |
| AR (1) | AR078619A1 (xx) |
| AU (1) | AU2010305859A1 (xx) |
| BR (1) | BR112012008962A2 (xx) |
| CA (1) | CA2776457A1 (xx) |
| CL (1) | CL2012000937A1 (xx) |
| ES (1) | ES2538005T3 (xx) |
| HK (1) | HK1179957A1 (xx) |
| IL (1) | IL218958A0 (xx) |
| IN (1) | IN2012DN03337A (xx) |
| MX (1) | MX2012004311A (xx) |
| PE (1) | PE20121732A1 (xx) |
| RU (1) | RU2607080C2 (xx) |
| TW (1) | TW201118068A (xx) |
| WO (1) | WO2011045292A1 (xx) |
| ZA (1) | ZA201202613B (xx) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2411395T3 (pl) | 2009-03-23 | 2013-10-31 | Glenmark Pharmaceuticals Sa | Pochodne furopirymidynodionu jako modulatory TRPA1 |
| US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US8722721B2 (en) * | 2011-03-16 | 2014-05-13 | Hoffmann-La Roche Inc. | SEC-hydroxycyclohexyl derivatives |
| US8703807B2 (en) | 2011-03-17 | 2014-04-22 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
| US8809384B2 (en) * | 2011-03-25 | 2014-08-19 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
| CN103319395B (zh) * | 2013-04-08 | 2014-09-24 | 武汉罗化科技有限公司 | 一种4-氟靛红的工业化制备方法及其产品 |
| WO2015103756A1 (en) * | 2014-01-09 | 2015-07-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| ES2933184T3 (es) | 2017-11-01 | 2023-02-02 | Bristol Myers Squibb Co | Compuestos espirocíclicos como moduladores del receptor farnesoide X |
| SG11202003827YA (en) | 2017-11-01 | 2020-05-28 | Bristol Myers Squibb Co | Bridged bicyclic compounds as farnesoid x receptor modulators |
| KR20200081436A (ko) | 2017-11-01 | 2020-07-07 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 화합물 |
| US11286252B2 (en) | 2017-11-01 | 2022-03-29 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| KR20200081435A (ko) | 2017-11-01 | 2020-07-07 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물 |
| CN109369354B (zh) * | 2018-12-15 | 2021-07-09 | 浦拉司科技（上海）有限责任公司 | 一种4,4,4-三氟丁醇的合成方法 |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| EP1697356B1 (en) | 2003-12-16 | 2008-02-27 | Pfizer Products Incorporated | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| FR2870538B1 (fr) * | 2004-05-19 | 2006-07-14 | Servier Lab | Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| DK2021337T3 (da) * | 2006-04-25 | 2010-03-29 | Lilly Co Eli | Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1 |
| WO2007127763A2 (en) | 2006-04-25 | 2007-11-08 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| GB0705656D0 (en) | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
-
2010
- 2010-10-08 US US12/900,621 patent/US8440710B2/en not_active Expired - Fee Related
- 2010-10-12 CN CN201080046313.0A patent/CN102858743B/zh not_active Expired - Fee Related
- 2010-10-12 KR KR1020127012343A patent/KR101576328B1/ko not_active IP Right Cessation
- 2010-10-12 WO PCT/EP2010/065232 patent/WO2011045292A1/en active Application Filing
- 2010-10-12 JP JP2012533604A patent/JP5749272B2/ja not_active Expired - Fee Related
- 2010-10-12 BR BR112012008962A patent/BR112012008962A2/pt not_active IP Right Cessation
- 2010-10-12 ES ES10770764.8T patent/ES2538005T3/es active Active
- 2010-10-12 MX MX2012004311A patent/MX2012004311A/es active IP Right Grant
- 2010-10-12 RU RU2012119706A patent/RU2607080C2/ru not_active IP Right Cessation
- 2010-10-12 AU AU2010305859A patent/AU2010305859A1/en not_active Abandoned
- 2010-10-12 IN IN3337DEN2012 patent/IN2012DN03337A/en unknown
- 2010-10-12 TW TW099134747A patent/TW201118068A/zh unknown
- 2010-10-12 CA CA2776457A patent/CA2776457A1/en not_active Abandoned
- 2010-10-12 PE PE2012000489A patent/PE20121732A1/es not_active Application Discontinuation
- 2010-10-12 EP EP10770764.8A patent/EP2488493B1/en not_active Not-in-force
- 2010-10-13 AR ARP100103732A patent/AR078619A1/es unknown
-
2012
- 2012-03-29 IL IL218958A patent/IL218958A0/en unknown
- 2012-04-11 ZA ZA2012/02613A patent/ZA201202613B/en unknown
- 2012-04-13 CL CL2012000937A patent/CL2012000937A1/es unknown
-
2013
- 2013-06-19 HK HK13107152.4A patent/HK1179957A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2538005T3 (es) | 2015-06-16 |
| RU2607080C2 (ru) | 2017-01-10 |
| KR20120074304A (ko) | 2012-07-05 |
| BR112012008962A2 (pt) | 2019-09-24 |
| RU2012119706A (ru) | 2013-11-20 |
| JP2013507421A (ja) | 2013-03-04 |
| IL218958A0 (en) | 2012-06-28 |
| TW201118068A (en) | 2011-06-01 |
| EP2488493A1 (en) | 2012-08-22 |
| US20110092512A1 (en) | 2011-04-21 |
| AU2010305859A1 (en) | 2012-06-07 |
| JP5749272B2 (ja) | 2015-07-15 |
| CN102858743A (zh) | 2013-01-02 |
| CN102858743B (zh) | 2015-06-10 |
| IN2012DN03337A (xx) | 2015-10-23 |
| US8440710B2 (en) | 2013-05-14 |
| PE20121732A1 (es) | 2012-12-28 |
| CA2776457A1 (en) | 2011-04-21 |
| EP2488493B1 (en) | 2015-04-15 |
| ZA201202613B (en) | 2013-01-30 |
| AR078619A1 (es) | 2011-11-23 |
| KR101576328B1 (ko) | 2015-12-10 |
| MX2012004311A (es) | 2012-04-30 |
| CL2012000937A1 (es) | 2012-09-14 |
| WO2011045292A1 (en) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1179957A1 (en) | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes hsl - | |
| ZA201700326B (en) | Inhibitors of beta-secretase | |
| HK1148435A1 (en) | Oxadiazoanthracene compounds for the treatment of diabetes | |
| ZA200902374B (en) | Compositions useful for the treatment of diabetes | |
| ZA201203615B (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| ZA201006827B (en) | Carboxamide-heteroaryl derivatives for the treatment of diabetes | |
| WO2010115061A9 (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| HK1169993A1 (en) | Hsl inhibitors useful in the treatment of diabetes hsl | |
| IL206904A0 (en) | Beta--amino acid derivatives for treatment of diabetes | |
| IL219138A0 (en) | Process for the preparation of 4-sulfinyl-pyrazole derivatives | |
| IL207431A0 (en) | New process for the preparation of cyclohexanecarboxylic acid derivatives | |
| HK1190706A1 (en) | Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes hsl - | |
| IL211267A0 (en) | Oxadiazole derivatives for the treatment of diabetes | |
| PL2323625T3 (pl) | Nowa kompozycja do leczenia pigmentacji wybroczynowych | |
| ZA201108702B (en) | Piperidine derivatives useful for treatment of diabetes | |
| EP2498794A4 (en) | METHOD FOR THE TREATMENT OF TYPE-2 DIABETES | |
| GB0913427D0 (en) | Compounds for treatment of imflammation | |
| GB0906210D0 (en) | Compounds for the treatment of flaviviral | |
| AU2009903360A0 (en) | Method of Treatment | |
| GB0802903D0 (en) | Treatment of diabetes | |
| ZA201107562B (en) | Compound for the treatment of tuberculosis | |
| IL207753A0 (en) | Substituted 4-aminocyclohexane derivatives for the treatment of pain | |
| ZA200907778B (en) | Method of treating diabetes | |
| AU2009905268A0 (en) | Method for the treatment of cardiovascular diseases | |
| AU2009905269A0 (en) | Method for the treatment of cardiovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191015 |